Proof of Concept Study to Compare Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Nonsegmental Vitiligo (CUV102)

NCT01430195 Phase 1 COMPLETED

The purpose of this study is to look at the efficacy of afamelanotide, when combined with narrow-band ultraviolet B (NB-UVB) light, in patients with nonsegmental vitiligo. Afamelanotide is expected to speed up the repigmentation induced by NB-UVB light, leading to reducing frequency and doses of NB-UVB.

Details

Lead sponsor	Clinuvel Pharmaceuticals Limited
Phase	Phase 1
Status	COMPLETED
Enrolment	56
Start date	2011-06
Completion	2012-11

Conditions

• Vitiligo

Interventions

• Afamelanotide
• Narrow-Band UVB Light Treatment

Primary outcomes

• Pigmentation of full body, face, trunk and extremities using the VASI and VETF scores — 6 months

Countries

United States